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There is no consensus and little information avail-
able regarding the suitability of administration of antican-
cer agents in patients with insufficient renal function who
are undergoing treatment by continuous ambulatory peri-
toneal dialysis (CAPD) or hemodialysis. In CAPD, the
dialysate is infused into the peritoneum through an in-
dwelling catheter with the tip positioned in the pelvis, and
the peritoneal membrane, a natural semipermeable mem-
brane, serves as the dialyzer. CAPD is done at home,
usually four or five times every day. Pharmacokinetic and
pharmacodynamic analyses of anticancer agents in such
patients are thus needed so that potential adverse events
can be predicted and avoided. The cytotoxic drug do-
cetaxel is metabolized by hepatic cytochrome P450 and is
excreted through bile into feces.1 Renal excretion of the
drug is minimal (5%). However, it is not known whether
administration of docetaxel is safe in patients undergoing
CAPD. We now present the first full pharmacokinetic
analysis of docetaxel in a patient with non-small cell lung
cancer (NSCLC) undergoing CAPD.
Case Presentation
A 76-year-old man with chronic renal failure attrib-
uted to diabetic nephropathy presented with a mass in the
lower lobe of the left lung. Computed tomography (CT)-
guided needle biopsy yielded a diagnosis of lung adeno-
carcinoma. Chest CT revealed a metastasis in the other
lung and an enlarged hilar lymph node. The clinical stage
of the patient was T2N1M1. Physical examination of the
patient, who was undergoing CAPD, revealed no relevant
findings, even though blood tests showed blood urea ni-
trogen and creatinine levels of 29.0 and 9.2 mg/dl, respec-
tively. Other blood test parameters were within normal
limits. The Eastern Cooperative Oncology Group perfor-
mance status of the patient was 1.
The patient was treated with docetaxel at 60 mg/m2
over 60 minutes on day 1 every 3 weeks, the standard
recommended dose and scheduled in Japan. Diarrhea and
febrile neutropenia of grade 3 developed during the first cycle
but were manageable. Other adverse events included general
fatigue, appetite loss, and anemia, which were also generally
tolerable. Chest CT after two cycles of chemotherapy re-
vealed stable disease for both the primary and metastatic
lesions. However, subsequent chemotherapy was discontin-
ued because of patient refusal.
Blood samples were collected before the first do-
cetaxel infusion, 30 minutes after onset of the infusion, 5
minutes before the end of the infusion, as well as 0, 5, 10,
20, 30, 60, and 90 minutes and 2, 3, 4, 6, 8, 10, and 24
hours after infusion for pharmacokinetic analysis. The
plasma concentration of docetaxel was measured by high-
performance liquid chromatography.2 The postinfusion
plasma concentration of docetaxel showed a typical tripha-
sic profile (Figure 1).3 The area under the concentration-
time curve and plasma clearance of docetaxel were 2.11
g  h/ml and 25.1 L/h/m2, respectively, consistent with
values previously determined for patients with normal
renal function (Table 1).4
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FIGURE 1. Plasma concentration versus time curve for the
first cycle of docetaxel chemotherapy in the present case.
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DISCUSSION
Docetaxel is a key cytotoxic agent that shows marked
activity against several cancers, including NSCLC. CAPD
is an important renal replacement therapy for chronic renal
failure patients. However, there is little information avail-
able and no consensus regarding the suitability of do-
cetaxel administration in patients with insufficient renal
function. We now report the first full pharmacokinetic
analysis of docetaxel in a patient with NSCLC undergoing
CAPD. The analysis revealed that CAPD appeared to have
no effect on the pharmacokinetic parameters of docetaxel.
The occurrence and severity of adverse events associated
with docetaxel were also not increased as a result of the
reduced renal function of the patient. Our data thus indi-
cate that docetaxel administration was safe in the present
patient and did not result in deterioration in his perfor-
mance status. Pharmacokinetic and pharmacodynamic
analyses of anticancer agents in patients with renal insuf-
ficiency will help to establish appropriate treatments that
maximize efficacy while avoiding unacceptable toxicity.
Further evaluation of the contribution of renal function to
the efficacy and toxicity of docetaxel is warranted.
REFERENCES
1. Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of
docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in
humans. Cancer Res 1996;56:1296–1302.
2. Extra JM, Rousseau F, Bruno R, et al. Phase I and pharmacokinetic
study of Taxotere (RP 56976; NSC 628503) given as a short intravenous
infusion. Cancer Res 1993;53:1037–1042.
3. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin
Pharmacokinet 1999;36:99–114.
4. Yamamoto N, Tamura T, Murakami H, et al. Randomized pharmacoki-
netic and pharmacodynamic study of docetaxel: dosing based on body-
surface area compared with individualized dosing based on cytochrome
P450 activity estimated using a urinary metabolite of exogenous cortisol.
J Clin Oncol 2005;23:1061–1069.
TABLE 1. Pharmacokinetic Parameters for Docetaxel in the
Present Case Compared with Those (Mean  SD)
Determined in a Previous Study of 30 Japanese Patients with
Normal Renal Function4
Parameter Present Case Previous Study
Cmax (g/ml) 3.11 2.71  0.4
T1/2 (h) 15.5 9.2  3.3
AUC (g  h/ml) 2.11 2.71  0.4
Clearance (L/h/m2) 25.1 22.6  3.4
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